Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
2.040
+0.005 (0.25%)
Jul 25, 2025, 4:00 PM - Market closed

Company Description

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.

The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.

Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Innate Pharma S.A.
Innate Pharma logo
CountryFrance
Founded1999
IPO DateOct 17, 2019
IndustryBiotechnology
SectorHealthcare
Employees181
CEOJonathan Dickinson

Contact Details

Address:
117, Avenue de Luminy, BP 30191
Marseille, 13009
France
Phone33 4 30 30 30 30
Websiteinnate-pharma.com

Stock Details

Ticker SymbolIPHA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
IPO Price$5.50
CIK Code0001598599
CUSIP Number45781K204
ISIN NumberUS45781K2042
SIC Code2836

Key Executives

NamePosition
Jonathan E. Dickinson B.Sc., M.B.A.Chief Executive Officer
Yannis Morel Ph.D.Executive Vice President and Chief Operating Officer
Dr. Sonia Quaratino M.D., Ph.D.Executive Vice President and Chief Medical Officer
Dr. François Romagné Ph.D.Founder
Eric Vivier D.V.M., M.B.A., Ph.D.Founder, Senior Vice President and Chief Scientific Officer
Dr. Marc Bonneville Ph.D.Founder
Jean Jacques Fournié Ph.D.Founder
Alessandro Moretta M.D., Ph.D.Founder
Frederic Lombard M.B.A.Senior Vice President and Chief Financial Officer
Henry Wheeler M.Sc.Vice President of Investor Relations and Communication

Latest SEC Filings

DateTypeTitle
Jul 7, 20256-KReport of foreign issuer
Jun 17, 20256-KReport of foreign issuer
Jun 13, 20256-KReport of foreign issuer
May 30, 2025144Filing
May 27, 20256-KReport of foreign issuer
May 23, 20256-KReport of foreign issuer
May 23, 20256-KReport of foreign issuer
May 19, 20256-KReport of foreign issuer
May 15, 20256-KReport of foreign issuer
May 13, 20256-KReport of foreign issuer